3 November 2025

Botanix Proudly Supports Hyperhidrosis Awareness Month

Philadelphia PA and Phoenix AZ, 3 November 2025: Commercial dermatology company, Botanix Pharmaceuticals Ltd (ABN 70 009 109 755) (ASX: BOT, "Botanix" or "the Company"), is a proud supporter of November's Hyperhidrosis Awareness Month. We share the International Hyperhidrosis Society's belief that 'together, we can amplify the message that excessive, uncontrollable sweating is a serious medical condition warranting serious attention.'

The disproportionate sweat production that characterises hyperhidrosis, results in a disabling medical condition with profound effects on the patient's quality of life.[1] In the US alone, more than 16 million patients are impacted by primary hyperhidrosis, which can affect face, hands, feet and other areas of the body.

Botanix's *Sofdra*® (sofpironium) is the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis, also known as excessive underarm sweating. This is the third largest dermatologic condition (after acne and atopic dermatitis), which impacts approximately 10 million patients in the US.[2] It is a novel safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition.

Throughout November, Botanix sales professionals will enter dermatology offices with new materials designed to raise awareness of primary axillary hyperhidrosis and *Sofdra.* The Hyperhidrosis Awareness Month stickers shown at right will grace the Company's posters in waiting areas and exam rooms. A series of themed 'flash cards,' each reinforcing a key *Sofdra* message, is expected to invite conversations with healthcare providers throughout the month. Our sales professionals will wear a different lapel button each week to provoke curiosity and help initiate discussions. Botanix expects these promotions to stimulate primary axillary hyperhidrosis conversations between physicians and patients.

[1] Dolittle, et al, 2016, Hyperhidrosis: an update on prevalence and severity in the United States, Archives of Dermatology Research.
[2] Hamm H, Naumann MK, Kowalski JW, Kutt S, Kozma C, Teale C. Primary focal hyperhidrosis: disease characteristics and functional impairment. Dermatology. 2006;212(4):343–353. doi: 10.1159/000092285

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (US) which has received FDA approval for its lead product *Sofdra* for the treatment of primary axillary hyperhidrosis. *Sofdra* is the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis and presents a novel safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition.

To learn more please visit: http://www.botanixpharma.com/

For more information, please contact:

General enquiries
Corporate Communications
Botanix Pharmaceuticals
P: +61 8 6555 2945
investors@botanixpharma.com

Investor enquiries
Hannah Howlett
WE Communications
P: +61 450 648 064
hhowlett@we-worldwide.com

Media enquiries
Haley Chartres
H^CK
P: +61 423 139 163
haley@hck.digital

***Sofdra* Important Safety Information & Indication**

Indication

Sofdra (sofpironium) topical gel, 12.45% is a prescription anticholinergic medicine used on the skin (topical) to treat excessive underarm sweating (primary axillary hyperhidrosis) in adults and children 9 years of age and older.

IMPORTANT SAFETY INFORMATION

***Sofdra* is for use on the skin in the underarm area only. Wash your hands right away after you apply *Sofdra*. Do not touch your underarms after applying *Sofdra*. *Sofdra* is flammable. Avoid heat and flame while applying *Sofdra*.**

Who should not use *Sofdra*?

Do not use *Sofdra* if you have certain medical conditions that can be made worse by taking an anticholinergic medicine such as glaucoma, severe ulcerative colitis (UC) or certain other serious bowel problems associated with severe UC, myasthenia gravis, and Sjogren's syndrome.

What should I tell my healthcare provider before using *Sofdra*?

- **Tell your healthcare provider about all of your medical conditions,** including bladder or kidney problems, problems passing urine, if you are pregnant or breastfeeding, or plan to become pregnant or breastfeed. It is not known if *Sofdra* will harm your unborn baby or pass into your breast milk.
- **Tell your healthcare provider about all the medicines you take,** including prescription and over-the-counter medicines, especially any anticholinergic medicines.

What are possible side effects of *Sofdra*?

Serious side effects may include:

- **Blurred vision.** Stop using *Sofdra*, call your healthcare provider right away, and do not drive or operate machinery or do hazardous work until your vision is clear.
- **New or worsened urinary retention.** Stop using *Sofdra* and call your healthcare provider right away if you experience difficulty urinating, urinating frequently, urination in a weak stream or drips, full bladder or difficulty emptying your bladder.

The most common side effects of *Sofdra* include dry mouth; blurred vision; pain, redness, swelling, itching, and irritation in the underarm area; dilation of the pupils of your eyes (mydriasis); and problems with urination. These are not all of the possible side effects of *Sofdra*. Call your doctor for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Botanix at 1-866-763-6337.

Keep *Sofdra* and all medicines out of the reach of children.